Catherine Schulte; Analyst; Robert W. Baird & Co. Inc. Welcome, everyone, to Natera's 2024 fourth-quarter financial results conference call. (Operator Instructions) As a reminder, this conference call ...

In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Natera (NTRA – Research Report), with a price target of $200.00. The company’s shares closed ...

“We had a strong finish to the year, with excellent performance across the board,” said Steve Chapman, chief executive officer of Natera. “Our ongoing success can be attributed to the ...

Genetic testing company Natera (NASDAQ:NTRA). reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 53% year on year to $476.1 million. The company’s full-year revenue ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended ...

Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results tomorrow after market close. Here’s what to look for. Natera beat analysts’ revenue expectations by 21.5% last ...

A federal judge threw out Natera Inc.'s $96.3 million verdict win against CareDx Inc., voiding two patents for detecting organ-transplant rejections—including one a jury found two of CareDx’s ...

Natera (NTRA) announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid Services’ Molecular Diagnostics Services Program for patients with non ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid ...

Shares of Natera stock opened at $158.37 on Tuesday. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The company’s 50-day simple moving average ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Signatera test has met coverage requirements from the ...